ClinicalTrials.gg
Temporarily not availableNCT06980519Updated Sep 4, 2026

MNPR-101-PCTA-177Lu Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

An expanded access record providing MNPR-101-PCTA-177Lu in Cancer, Solid Tumor and Solid Tumor Cancer, sponsored by Monopar Therapeutics. Temporarily not available at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-04.

Sponsored by Monopar Therapeutics · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Intermediate-size population
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational therapeutic agent, MNPR-101-PCTA-177Lu, for treatment of urokinase plasminogen activator receptor (uPAR)-positive solid tumors identified via positron emission tomography / computed tomography (PET/CT) with investigational imaging agent MNPR-101-DFO*-89Zr.

Read the detailed description

This EAP will enroll patients with uPAR-positive solid tumor cancer confirmed by prior PET/CT imaging with MNPR-101-DFO*-89Zr (EAP IST-00Ca). Eligible patients will be treated with 1 cycle (as 2 fractionated doses) of investigational therapy, MNPR-101-PCTA-177Lu, at 1 of 4 planned dose levels. All enrolled patients will receive active treatment. Dosing of patients will begin at the lowest planned dose level. After 2 patients are dosed at a level, the next 2 patients may receive the next higher dose level, the same dose level, or a lower dose level, based upon the nature and severity of adverse reactions (side effects). The safety, tolerability, and potential antitumor effects (radiologic response) of MNPR-101-PCTA-177Lu will be evaluated over 12 weeks after dosing. The amount of radioactivity in blood samples will be checked over 4 weeks post dose. Patient survival will be followed up 6 months after the last dose received.

02

Conditions studied

  • Cancer
  • Solid Tumor
  • Solid Tumor Cancer
  • Oncology
  • uPAR-positive Solid Tumor
  • Urokinase Plasminogen Activator Receptor-positive Solid Tumor

Browse trials for

Keywords

  • MNPR-101-PCTA-177Lu
  • SPECT
  • SPECT/CT
  • CT
  • Radiotherapy
  • Radiologic response
  • Single Photon Emission Computed Tomography
  • Computed Tomography
  • Monoclonal antibody radionuclide conjugate
  • Antibody radionuclide conjugate
  • Lutetium-177
  • Single Photon Emission Computed Tomography/Computed Tomography
  • Urokinase plasminogen activator receptor-positive
  • uPAR-positive
  • Positron emission tomography/computed tomography
  • PET/CT
  • EAP IST-00Ca
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

Browse Neoplasms studies →

Lead sponsor

Monopar Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All

Eligibility criteria

Key Inclusion Criteria:

  • Participated in the Expanded Access Program (EAP) IST-00Ca study
  • or cytologically confirmed locally advanced or solid tumor cancer that is to existing therapy(ies) known to provide clinical benefit, or for which no standard treatment is available, or is
  • Ability to understand and willingness to sign a written document

Key Exclusion Criteria:

  • Chemotherapy, radiotherapy (other than short cycle of palliative radiotherapy), or immunotherapy within 14 days prior to administration of MNPR-101-PCTA-177Lu
  • Continuing ≥ Grade 3 adverse reactions from prior systemic therapy ( [CTCAE] version 5.0)
  • Prior treatment with any radiopharmaceutical or agents within 4 weeks or 5 half-lives, whichever is longer, prior to administration of the first dose of MNPR-101-PCTA-177Lu other than MNPR-101-DFO*-89Zr
  • Evidence of impaired organ function, particularly bone marrow, liver, kidney, or heart, according to specific test parameters
  • Presence of other serious, non-malignant diseases or any other condition that, in the opinion of the investigator, could interfere with the objectives of the study, participant safety, or compliance
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Access details

Study type
Expanded access
Access type
Intermediate-size population

Available treatment

  • BiologicalMNPR-101-PCTA-177Lu

    MNPR-101-PCTA-177Lu is a monoclonal antibody-radionuclide conjugate intended to target and deliver radioactivity to solid tumors expressing uPAR.

06

Where to request access

1 site
  • Excel Diagnostics & Nuclear Oncology Center
    Houston, Texas 77042, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT06980519
Lead sponsor
Monopar Therapeutics
Responsible party
Sponsor
First posted
May 20, 2025
Last update
Sep 4, 2026

Study contacts

Ebrahim S. Delpassand, M.D. Chairman & Medical Director, Nuclear Medicine
principal investigator · Excel Diagnostics & Nuclear Oncology Center
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion